
Ask a doctor about a prescription for Diclac 50
Diclac 50(Diclac 50 mg Suppositories)
Diclofenac sodium
Diclac 50 and Diclac 50 mg Suppositories are different trade names for the same medicine
Diclac 50 contains diclofenac sodium, which belongs to the group of non-steroidal anti-inflammatory drugs (NSAIDs), acting as anti-rheumatic, anti-inflammatory, analgesic, and antipyretic agents. The mechanism of action of Diclac 50 involves the inhibition of prostaglandin biosynthesis, which plays a fundamental role in the pathogenesis of inflammation, pain, and fever.
Diclac 50 is used to treat:
In patients with diagnosed heart disease or significant risk factors for cardiovascular disease, the treating physician will periodically assess the patient's need for symptomatic treatment and their response to the medicine, especially if the treatment lasts longer than 4 weeks.
During treatment, the physician will order regular blood tests to monitor liver function (aminotransferase activity), kidney function (creatinine levels), and blood cell count (white and red blood cells and platelets). Based on the test results, the physician will decide whether to discontinue treatment with Diclac 50 or change the dose of the medicine.
The patient should inform their doctor about the presence of these diseases.
Before using Diclac 50, the patient should discuss it with their doctor if:
If any unusual abdominal symptoms occur during the use of Diclac 50 (especially gastrointestinal bleeding), the medicine should be discontinued immediately and the patient should consult a doctor;
the patient has ulcerative colitis or Crohn's disease, as diclofenac may exacerbate the course of the disease;
Before taking Diclac 50, the patient should inform their doctor if:
The occurrence of side effects can be limited by using the medicine in the smallest effective dose and for no longer than necessary.
In order to minimize the risk of side effects, the smallest dose of Diclac 50 that provides pain and/or swelling relief should be used, and it should be used for the shortest possible time.
If at any time during the use of Diclac 50 the patient experiences symptoms indicating heart or vascular problems (such as chest pain, shortness of breath, weakness, or slurred speech), they should immediately consult a doctor or hospital emergency department.
The use of diclofenac may temporarily inhibit platelet aggregation.
Due to the dose, the use of Diclac 50 is not recommended in children and adolescents under the age of 14.
Elderly patients may react more strongly to the action of the medicine than other adult patients. The patient should follow the recommendations contained in the leaflet, use the smallest effective doses in accordance with the doctor's recommendations, and report all side effects that occur during treatment to their doctor.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The patient should inform their doctor especially about taking the following medicines:
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor before using this medicine.
Diclac 50 should not be used during the first two trimesters of pregnancy, unless the doctor considers it absolutely necessary.
As with other anti-inflammatory drugs, the use of Diclac 50 in the last three months of pregnancy is contraindicated, as it may seriously harm the fetus or have an adverse effect on delivery.
Diclac 50 may cause kidney and heart problems in the unborn child. It may also increase the risk of bleeding in the patient and the child, as well as prolong or delay labor.
From the 20th week of pregnancy, Diclac 50 may cause kidney function disorders in the unborn child if used for more than a few days. This may lead to a low level of amniotic fluid surrounding the child (oligohydramnios). If treatment is required for a period longer than a few days, the doctor may recommend additional monitoring.
Diclac 50 should not be used in breastfeeding women, as it may harm the infant.
The doctor will discuss the potential risks of using Diclac 50 during pregnancy and breastfeeding with the patient.
Taking Diclac 50 may make it difficult to become pregnant. If the patient plans to become pregnant or is having trouble becoming pregnant, they should inform their doctor.
The effect of Diclac 50 on the ability to drive vehicles, operate machinery, or perform other activities that require special attention is unlikely.
This medicine contains less than 1 mmol (23 mg) of sodium per suppository, which means the medicine is considered "sodium-free".
This medicine should always be used in accordance with the doctor's recommendations. In case of doubts, the patient should consult a doctor or pharmacist.
The recommended doses should not be exceeded. If Diclac 50 is used for more than a few weeks, the patient should regularly undergo medical check-ups to rule out any unnoticed side effects.
The dose of the medicine is determined by the doctor individually for each patient. The rule is to use the smallest effective dose for the shortest possible time.
If the patient feels that the effect of the medicine is too strong or too weak, they should consult a doctor.
A suppository should be inserted well into the rectum.
Adults
The recommended initial daily dose is 100 mg to 150 mg.
In milder cases and in chronic treatment, a dose of up to 100 mg per day is considered sufficient.
The total daily dose should be taken in 2 or 3 divided doses. To alleviate nighttime pain and morning stiffness, treatment with tablets during the day can be supplemented with a suppository before bedtime (without exceeding the maximum daily dose of 150 mg).
In primary dysmenorrhea, the daily dose should be determined individually for each patient. It usually ranges from 50 mg to 150 mg. Initially, 50 mg to 100 mg should be administered, and if necessary, the dose can be increased over several menstrual cycles to a maximum dose of 200 mg per day. Treatment should be started when the first symptoms appear and, depending on their severity, continued for several days.
Treatment of migraine attacks with Diclac 50 should be started with a dose of 100 mg administered after the first symptoms appear. If necessary, an additional suppository of up to 100 mg can be used on the same day. If the patient requires further treatment over the next few days, the maximum daily dose should be limited to 150 mg and taken in divided doses.
Use in children and adolescents
Diclac 50 in the form of suppositories containing 50 mg of diclofenac should not be used in children under the age of 14.
Depending on the severity of symptoms, from 0.5 mg/kg body weight to 2 mg/kg body weight per day, in 2 or 3 divided doses. The daily dose can be increased to a maximum of 3 mg/kg body weight in divided doses.
The daily dose should not exceed 150 mg.
The medicine should be used with caution in elderly patients. In elderly patients and those with low body weight, the smallest effective dose is recommended.
Patients with diagnosed cardiovascular disease or significant risk factors for cardiovascular events should be treated with diclofenac only after careful consideration and only with doses ≤100 mg per day if the treatment lasts longer than 4 weeks.
The use of Diclac 50 in patients with kidney failure is contraindicated.
No special studies have been conducted in patients with kidney function disorders, so no specific dosage recommendations can be made. In patients with mild to moderate kidney function disorders, caution is recommended.
The use of Diclac 50 in patients with liver failure is contraindicated.
No special studies have been conducted in patients with liver function disorders, so no specific dosage recommendations can be made. In patients with mild to moderate liver function disorders, caution is recommended.
It is recommended to use the suppositories after bowel movements.
Overdose of Diclac 50 does not cause characteristic symptoms, but the following may occur: vomiting, gastrointestinal bleeding, diarrhea, dizziness, tinnitus, or seizures.
In the case of significant poisoning, acute kidney failure and liver damage may occur.
In the event of accidental use of a larger amount of the medicine than recommended, the patient should immediately consult a doctor, pharmacist, or go to the hospital emergency department.
If the patient misses a dose, they should take it as soon as they remember.
However, if more than half of the time between two doses has passed, the missed dose should not be taken, and the next dose should be taken according to the previous dosing schedule. A double dose should not be taken to make up for the missed dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects are described below for diclofenac in the form of suppositories and diclofenac in other pharmaceutical forms, used for short or long periods.
Common(may occur in less than 1 in 10 people using the medicine):
Uncommon(may occur in less than 1 in 100 people using the medicine):
Rare(may occur in less than 1 in 1000 people using the medicine):
Very rare(may occur in less than 1 in 10,000 people using the medicine):
Frequency not known(frequency cannot be estimated from the available data):
Taking medicines like Diclac 50 may be associated with a small increased risk of heart attack (myocardial infarction) or stroke.
In some people, during the use of Diclac 50, other side effects may occur.
If any of the side effects worsen or any side effects not listed in this leaflet occur, the patient should tell their doctor or pharmacist.
These uncommon side effects may occur in 1 to 10 patients out of 1000, especially when using high daily doses (150 mg) for a long time
If the patient uses Diclac 50 for more than a few weeks, they should regularly consult their doctor to ensure that no side effects have occurred.
Reporting suspected side effects
If side effects occur, including any side effects not listed in this leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C, 02-222 Warsaw
Phone: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored in a place invisible and inaccessible to children.
Do not store at a temperature above 25°C
Do not use after the expiration date stated on the package. The expiration date indicates the last day of the specified month.
Translation of some information on the immediate packaging:
Ch.-B./verw. bis: see imprint – batch number/expiration date: see imprint.
Medicines should not be thrown into the sewage system or household waste containers. The patient should ask their pharmacist what to do with medicines that are no longer needed. This will help protect the environment.
The active substance of the medicine is diclofenac sodium. One suppository contains 50 mg of diclofenac sodium.
In addition, the medicine contains solid fat.
Blisters in a cardboard box.
The package contains 10 suppositories.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
Hexal AG
Industriestraße 25
83607 Holzkirchen
Germany
Salutas Pharma GmbH
Otto-von-Guericke-Allee 1
39179 Barleben
Germany
Medezin Sp. z o.o.
Zbąszyńska Street 3
91-342 Łódź
Medezin Sp. z o.o.
Zbąszyńska Street 3
91-342 Łódź
CEFEA Sp. z o.o. Sp. komandytowa
Działkowa Street 56
02-234 Warsaw
SHIRAZ PRODUCTIONS Sp. z o.o.
Tymiankowa Street 24/28
95-054 Ksawerów
CANPOLAND SPÓŁKA AKCYJNA
Beskidzka Street 190
91-610 Łódź
Marketing authorization number in Germany, the country of export: 6360.00.02
[Information about the trademark]
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Diclac 50 – subject to medical assessment and local rules.